These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1373672)

  • 1. Tumor-inhibitory monoclonal antibodies to the HER-2/Neu receptor induce differentiation of human breast cancer cells.
    Bacus SS; Stancovski I; Huberman E; Chin D; Hurwitz E; Mills GB; Ullrich A; Sela M; Yarden Y
    Cancer Res; 1992 May; 52(9):2580-9. PubMed ID: 1373672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer.
    Chang JY; Xia W; Shao R; Sorgi F; Hortobagyi GN; Huang L; Hung MC
    Oncogene; 1997 Feb; 14(5):561-8. PubMed ID: 9053854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
    Pietras RJ; Poen JC; Gallardo D; Wongvipat PN; Lee HJ; Slamon DJ
    Cancer Res; 1999 Mar; 59(6):1347-55. PubMed ID: 10096569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
    De Santes K; Slamon D; Anderson SK; Shepard M; Fendly B; Maneval D; Press O
    Cancer Res; 1992 Apr; 52(7):1916-23. PubMed ID: 1348016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
    Pietras RJ; Fendly BM; Chazin VR; Pegram MD; Howell SB; Slamon DJ
    Oncogene; 1994 Jul; 9(7):1829-38. PubMed ID: 7911565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
    Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
    Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine kinase inhibitor emodin suppresses growth of HER-2/neu-overexpressing breast cancer cells in athymic mice and sensitizes these cells to the inhibitory effect of paclitaxel.
    Zhang L; Lau YK; Xia W; Hortobagyi GN; Hung MC
    Clin Cancer Res; 1999 Feb; 5(2):343-53. PubMed ID: 10037184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
    Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin.
    Zhang L; Chang CJ; Bacus SS; Hung MC
    Cancer Res; 1995 Sep; 55(17):3890-6. PubMed ID: 7543819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.
    Drebin JA; Link VC; Greene MI
    Oncogene; 1988 Apr; 2(4):387-94. PubMed ID: 2896329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A ligand for the erbB-2 oncogene product (gp30) induces differentiation of human breast cancer cells.
    Bacus SS; Huberman E; Chin D; Kiguchi K; Simpson S; Lippman M; Lupu R
    Cell Growth Differ; 1992 Jul; 3(7):401-11. PubMed ID: 1358180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
    Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
    Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical studies with Fc(gamma)R bispecific antibodies and granulocyte colony-stimulating factor-primed neutrophils as effector cells against HER-2/neu overexpressing breast cancer.
    Stockmeyer B; Valerius T; Repp R; Heijnen IA; Bühring HJ; Deo YM; Kalden JR; Gramatzki M; van de Winkel JG
    Cancer Res; 1997 Feb; 57(4):696-701. PubMed ID: 9044847
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neu differentiation factor (heregulin) induces expression of intercellular adhesion molecule 1: implications for mammary tumors.
    Bacus SS; Gudkov AV; Zelnick CR; Chin D; Stern R; Stancovski I; Peles E; Ben-Baruch N; Farbstein H; Lupu R
    Cancer Res; 1993 Nov; 53(21):5251-61. PubMed ID: 8106145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
    Arteaga CL; Winnier AR; Poirier MC; Lopez-Larraza DM; Shawver LK; Hurd SD; Stewart SJ
    Cancer Res; 1994 Jul; 54(14):3758-65. PubMed ID: 7913407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-Her-2/neu antibody induces apoptosis in Her-2/neu overexpressing breast cancer cells independently from p53 status.
    Brodowicz T; Kandioler D; Tomek S; Ludwig C; Rudas M; Kunstfeld R; Koestler W; Hejna M; Budinsky A; Wiltschke C; Zielinski CC
    Br J Cancer; 2001 Nov; 85(11):1764-70. PubMed ID: 11742500
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product.
    Fendly BM; Winget M; Hudziak RM; Lipari MT; Napier MA; Ullrich A
    Cancer Res; 1990 Mar; 50(5):1550-8. PubMed ID: 1689212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
    Pegram MD; Finn RS; Arzoo K; Beryt M; Pietras RJ; Slamon DJ
    Oncogene; 1997 Jul; 15(5):537-47. PubMed ID: 9247307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo.
    Spiridon CI; Ghetie MA; Uhr J; Marches R; Li JL; Shen GL; Vitetta ES
    Clin Cancer Res; 2002 Jun; 8(6):1720-30. PubMed ID: 12060609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.